What Pharma Medica Research does

Pharma Medica Research Inc. (PMRI) is a privately held, full-service Contract Research Organization (CRO) headquartered in Mississauga, Ontario, with an additional clinical site in Toronto. Founded in 1997, the company specializes in early-phase (Phase I-IV) clinical trials and bioanalytical testing, serving global pharmaceutical and biotechnology sponsors with an integrated offering that covers clinical study design and execution, GLP bioanalytical method development and validation, pharmacokinetic analysis, and regulatory submission support. The company operates from a 115,000+ sq ft facility that includes a 360-bed clinical site with a 24-bed Phase I Unit, a 65,000 sq ft GLP bioanalytical laboratory equipped with LC-MS/MS platforms, multiple Hamilton robots, and an on-site Organic Synthesis Lab for authentic reference standards.

The company's underlying technology is anchored by a proprietary, in-house developed Laboratory Data Management System (LDMS) and a 21 CFR Part 11 compliant software suite that automates data capture and assurance from clinic acquisition through laboratory analysis to final regulatory-compliant reports. Its bioanalytical portfolio includes 600+ validated assays with sub-pg/mL lower limits of quantification. Pharma Medica has passed regulatory inspections by FDA, EMA, AGES, MHRA, ANVISA, WHO, GCC, Health Canada, and the Standards Council of Canada, and holds a Topic Leader position on ICH M10 alongside active membership in the Global CRO Council.

The business operates on a professional services, project-based revenue model with quote-based B2B pricing; volunteers participating in studies are compensated on a pay-as-you-go basis of roughly $1,000-$2,500 per study. Go-to-market is direct enterprise sales to global pharma and biotech sponsors, supported by an introductory consultation offering. Leadership is founder/owner-operated under President and CEO Ilan Hofmann, and the company has remained independent since founding with no disclosed funding rounds, parent company, or institutional investment. Customer segments are horizontal across pharmaceutical and biotechnology sponsors, with a secondary focus on special and patient populations (psychiatric, respiratory, endocrine, allergy) in addition to healthy volunteers.

Name

Pharma Medica Research

Legal name

Pharma Medica Research Inc.

Website

https://pharmamedica.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Contract Research Organization Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical Trial Site Operations & Study Coordination (HLAGACAE), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Contract research services
• Clinical trial management
• Bioanalytical testing
• Pharmacokinetic analysis
• Early phase research

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations

Revenue model

1. Contract Research Services: Pharma Medica generates revenue through providing contract research organization services to pharmaceutical and biotechnology companies. Services include early phase clinical trials, bioanalytical testing, and scientific affairs support. Revenue is project-based, with each client engagement potentially spanning multiple studies and deliverables.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Pharma Medica Research is a full-service Contract Research Organization (CRO) delivering integrated early phase clinical trial services for global pharmaceutical and biotechnology sponsors. The company conducts Phase I-IV clinical trials at a 115,000+ square foot, 360-bed facility and provides GLP-compliant bioanalytical testing through a 65,000 square foot laboratory equipped with LC-MS/MS platforms and automated Hamilton robots. Services span study design, protocol development, pharmacokinetic analysis, biostatistics, regulatory submission support, and clinical study reporting under a proprietary 21 CFR Part 11 compliant technology infrastructure.

Product overview

Pharma Medica Research Inc. is a full-service Contract Research Organization (CRO) offering integrated early-phase clinical trial services. The company operates four interconnected service lines: Clinical Services (Phase I-IV trial execution at a 115,000+ sq ft, 360-bed facility), Bioanalytical Services (65,000 sq ft GLP laboratory with 600+ validated assays), Scientific Affairs (trial design, pharmacokinetics, and regulatory submissions), and Innovation & Quality (proprietary digital systems ensuring regulatory compliance). These services are designed to function as an all-inclusive package delivering submission-ready study deliverables for pharmaceutical and biotechnology sponsors.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Services

Quantifiable outcome

• 100% regulatory compliance and successful audit record across FDA, EMA, MHRA, and other major agencies
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Global CRO Council (GCC)coreOthersActive member of the Global CRO Council, an industry organization setting standards and best practices for clinical research organizations globally. This membership enables participation in industry standardization initiatives and peer collaboration.
• ICH M10 Topic LeadershipflagshipStrategic or Co-development PartnerPharma Medica holds a prominent leadership role as Topic Leader for ICH M10 (International Council for Harmonisation guideline on bioanalytical method validation), demonstrating active contribution to pioneering innovation and setting industry standards in bioanalysis globally.

Scale indicators6 records

Recent moves2 records

Expansion highlights6 records

Direct peers

• Celerion: Celerion is a closely comparable early-phase clinical CRO with deep bioanalytical capabilities serving global pharma and biotech sponsors. Like PMRI it specializes in Phase I trials, bioequivalence, and PK studies, making it the most direct head-to-head competitor.
• BioAgilytix Labs: BioAgilytix is a bioanalytical-focused CRO with large- and small-molecule assay capabilities serving pharma and biotech. It overlaps directly with PMRI's 600+ validated assay portfolio and GLP bioanalytical laboratory offering.
• Frontage Laboratories: Frontage provides bioanalytical, preclinical, and early-phase clinical services with a comparable integrated offering. It is a direct peer in both bioanalytical assay depth and early clinical execution for global sponsors.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size global CRO with strong early-phase and bioanalytical capabilities, frequently competing with PMRI for Phase I, bioequivalence, and complex study work from mid-sized pharma sponsors.

Broad incumbents

• ICON plc: ICON is one of the largest global CROs offering Phase I–IV clinical and bioanalytical services. As a broad incumbent it competes for the same pharma and biotech sponsor spend but at much greater scale across therapeutic areas and geographies.
• IQVIA: IQVIA is the largest global CRO and life sciences services provider. While its early-phase/bioanalytical unit overlaps with PMRI's offerings, IQVIA competes primarily through full-service, multi-region programs rather than specialty early-phase depth.
• Labcorp Drug Development (formerly Covance): Labcorp Drug Development operates one of the largest central/bioanalytical laboratory networks globally. It is a broad incumbent competing for both PMRI's clinical trial work and its central bioanalytical assay volume.
• Charles River Laboratories: Charles River provides research models, preclinical, and bioanalytical/CDMO services. While heavier on preclinical, its bioanalytical and safety assessment lines overlap with PMRI's GLP bioanalytical offering.
• Parexel International: Parexel is a global full-service CRO competing for Phase I–IV programs from large pharma. Its early clinical and bioanalytical groups overlap with PMRI, though Parexel's scale and therapeutic breadth are much larger.
• SGS Health Sciences (SGS Life Sciences): SGS Health Sciences provides bioanalytical, clinical, and quality services across multiple regions. As a broad life-sciences services incumbent it competes with PMRI for global bioanalytical and early-phase trial work, particularly in Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharma-medica-research-inc-/jobs
• Xx.com/pharma_medica

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Medica Research